FGFR2 and cholangiocarcinoma: Based on the advantages of NGS testing and past practical experience, the latest NCCN and ESMO guidelines recommend it as a detection method for FGFR2 fusion/other FGFR aberrations in cholangiocarcinoma [77, 86].